FDA Public Meeting: FDA-Led Patient-Focused Drug Development Meeting for Nonhealing Chronic Wounds August 25, 2026

https://www.fda.gov/drugs/news-events-human-drugs/fda-public-meeting-fda-led-patient-focused-drug-development-meeting-nonhealing-chronic-wounds?utm_medium=email&utm_source=govdelivery Public Meeting on Patient-Focused Drug Development for Nonhealing Chronic Wounds On August 25, 2026, FDA is hosting a hybrid public meeting on Patient-Focused Drug Development (PFDD) for Nonhealing Chronic Wounds. This meeting will provide FDA and other key stakeholders, including medical product developers, health care providers, and academic researchers, the opportunity to hear directly from patients, patient representatives, and care partners about their experiences with nonhealing chronic wounds, including how the wounds and associated wound care affect their daily life, what matters most to them, their current approaches for managing or treating their nonhealing chronic wounds, and what they consider when determining whether to participate in a clinical trial. There will be three sessions focused on: (1) health effects and daily impacts, (2) current approaches to treatment, and (3) perspectives on clinical trials. For each topic, a brief initial patient panel discussion will begin the dialogue. This will be followed by a facilitated discussion inviting comments from other patient and care partner participants in the audience. Panelists are also welcome to participate in the facilitated discussion. Meeting Logistics and Registration Date: August 25, 2026 Time: 10:00 a.m. – 4:30 p.m. ET Registration: https://www.fda.gov/pfddchronicwounds Location: Attend In Person or Online Virtual: Via Webcast In Person: FDA White Oak Campus, 10903 New Hampshire Ave, Building 31, Room 1503, Silver Spring, MD 20993 Panelists Patients or care partners interested in providing comments as part of the panel discussion are asked to indicate their interest when they register for the meeting. A member of our PFDD Staff will contact them via email. Panelists will be confirmed prior to the meeting and will be invited to a brief one-on-one call with our team to help prepare for their role in the discussion.